TRDA
Entrada Therapeutics Inc

198
Mkt Cap
$415.83M
Volume
183,478.00
52W High
$13.82
52W Low
$4.93
PE Ratio
-4.35
TRDA Fundamentals
Price
$10.88
Prev Close
$10.80
Open
$10.82
50D MA
$10.77
Beta
1.26
Avg. Volume
256,617.95
EPS (Annual)
$1.68
P/B
1.22
Rev/Employee
$1.15M
$313.57
Loading...
Loading...
News
all
press releases
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Hold" by Brokerages
Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) have been given a consensus rating of "Hold" by the five analysts that are presently covering the firm, Marketbeat.com reports...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +7.42% and +0.35%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Techne (TECH) Beats Q2 Earnings and Revenue Estimates
Techne (TECH) delivered earnings and revenue surprises of +8.24% and +1.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors
Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors There are just nine days left in the year, and this year has flown by. We've delivered readers a steady stream of 2026...
Zero Hedge·2mo ago
News Placeholder
5AM Venture Management LLC Has $28.95 Million Stake in Entrada Therapeutics, Inc. $TRDA
5AM Venture Management LLC trimmed its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 2.3% in the 2nd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·2mo ago
News Placeholder
Kory James Wentworth Sells 8,910 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 8,910 shares of Entrada Therapeutics stock in a transaction dated Friday, November 21st. The stock was sold at...
MarketBeat·3mo ago
News Placeholder
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the firm...
MarketBeat·3mo ago
News Placeholder
Ventures L.P. 5Am Sells 200,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures L.P. 5Am sold 200,000 shares of Entrada Therapeutics stock in a transaction that occurred on Friday, November...
MarketBeat·3mo ago
News Placeholder
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells 200,000 Shares of Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Kush Parmar sold 200,000 shares of the company's stock in a transaction on Friday, November 14th. The stock was sold at an average...
MarketBeat·3mo ago
News Placeholder
Insider Buying: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Buys 30,874 Shares of Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bros. Advisors Lp Baker acquired 30,874 shares of the firm's stock in a transaction dated Monday, November 10th. The stock...
MarketBeat·3mo ago
<
1
2
...
>

Latest TRDA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.